4974.T
Latest Trade
2,077.00JPYChange
17.00(+0.83%)Volume
129,500Today's Range
-
2,091.0052 Week Range
-
2,829.00As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 2,060.00 |
|---|---|
Open | 2,061.00 |
Volume | 129,500 |
3M AVG Volume | 8.24 |
Today's High | 2,091.00 |
Today's Low | 2,061.00 |
52 Week High | 2,829.00 |
52 Week Low | 1,943.00 |
Shares Out (MIL) | 120.42 |
Market Cap (MIL) | 248,056.10 |
Forward P/E | 56.15 |
Dividend (Yield %) | 0.34 |
Takara Bio signs agreement for co-development and sales rights in Japan to NY-ESO-1 siTCRTM and CD19 CAR gene therapies
Takara Bio say first patient enrolled into phase I clinical trial of Oncolytic Virus HF10 in Japan
Takara Holdings' subsidiary Takara Bio says merger between US-based units
TAKARA BIO INC. is a Japan-based company principally engaged in bio-industry support business and gene medicine business. The Company operates in three business segments. Bioindustry Support segment provides reagents for research (genetic engineering reagents, cell engineering reagents, protein engineering reagents), scientific instruments, contract services and license fees for gene related patents to research institutes, such as universities and companies where biotechnology research and development are conducted. Gene Medicine segment provides gene therapy-related development and sale licensing fees and trial products as an application field of genetic engineering technology and cell engineering technology which is core technology cultivated in development of research reagents. Medical Food and Biotechnology segment provides health food and health food research and development services, license fees for health food related patents, as well as license fees for mushrooms.
Industry
Biotechnology & Drugs
Executive Leadership
Hisashi Ohmiya
Chairman of the Board
Koichi Nakao
President, Executive President, President of Subsidiary, Representative Director
Masaharu Watabe
Managing Executive Officer, Director of Finance
Shuichiro Matsuzaki
Vice President, Executive Vice President, Director
Junichi Mineno
Managing Director, Managing Executive Officer, Chief Director of Bio-Industry Support Business Division, Manager of CDM Center
Price To Earnings (TTM) | 61.83 |
|---|---|
Price To Sales (TTM) | 7.10 |
Price To Book (MRQ) | 3.85 |
Price To Cash Flow (TTM) | 34.22 |
Total Debt To Equity (MRQ) | 0.00 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | 6.25 |
Return on Equity (TTM) | 5.79 |
* Says the first patient with pancreatic cancer has been enrolled into Oncolytic Virus HF10(TBI-1401) phase I clinical trial in Japan on Sept. 26
* Says it started first test of Phase II clinical trial of HF10, which will be used for treatment in patients with unresectable or metastatic melanoma, on May 26
* Says the company's wholly owned US-based sub-subsidiary Takara Bio USA Inc plans to merge with co's other two wholly owned US-based sub-subsidiaries Rubicon Genomics Inc and WaferGen Bio-systems Inc, with effective date on March 31 (for Rubicon) and May 31 (for WaferGen...
* Says the co to start phase I/II clinical trials of gene therapy for treatment of sarcoma
* Says its wholly owned subsidiary Takara Bio USA Holdings Inc completes acquisition of Rubicon Genomics, Inc on Jan. 17 (US local time)
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.